Scientists suggested that targeting of glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) in colorectal cancer might contribute to a new therapeutic strategy that was based on suppression of Wnt signaling and epithelial-mesenchymal transition-related cancer progression driven by cancer stem cells.
[Journal of Biochemistry]
